Toll Free: 1-888-928-9744

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2016

Published: May 31, 2016 | Pages: 912 | Publisher: GlobalData | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2016

Summary

GlobalData's clinical trial report, "Glioblastoma Multiforme (GBM) Global Clinical Trials Review, H1, 2016" provides an overview of Glioblastoma Multiforme (GBM) clinical trials scenario. This report provides top line data relating to the clinical trials on Glioblastoma Multiforme (GBM). Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData's proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons To Buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 4 Report Guidance 5 Clinical Trials by Region 6 Clinical Trials and Average Enrollment by Country 7 Top Five Countries Contributing to Clinical Trials in Asia-Pacific 9 Top Five Countries Contributing to Clinical Trials in Europe 10 Top Countries Contributing to Clinical Trials in North America 11 Top Five Countries Contributing to Clinical Trials in Middle East and Africa 12 Top Five Countries Contributing to Clinical Trials in Central and South America 13 Clinical Trials by G7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 14 Clinical Trials by Phase in G7 Countries 15 Clinical Trials in G7 Countries by Trial Status 16 Clinical Trials by E7 Countries: Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials 17 Clinical Trials by Phase in E7 Countries 18 Clinical Trials in E7 Countries by Trial Status 19 Clinical Trials by Phase 20 In Progress Trials by Phase 21 Clinical Trials by Trial Status 22 Clinical Trials by End Point Status 23 Subjects Recruited Over a Period of Time 24 Clinical Trials by Sponsor Type 25 Prominent Sponsors 26 Top Companies Participating in Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials 27 Prominent Drugs 28 Latest Clinical Trials News on Glioblastoma Multiforme (GBM) 29 May 06, 2016: ImmunoCellular Therapeutics Receives Regulatory Approval in Canada, the UK and the Netherlands to Initiate ICT-107 Phase 3 Trial in Newly Diagnosed Glioblastoma 29 May 02, 2016: NW Bio Announces Update On DCVax-L 29 Apr 25, 2016: FDA Approves Investigational Device Exemption for RTOG Trial of Novocure's Optune together with Bevacizumab for Patients with Bevacizumab-Refractory Recurrent Glioblastoma 29 Apr 21, 2016: TRACON Announces Presentation Of Clinical Data for TRC105 at ASCO Annual Meeting 30 Apr 21, 2016: Basilea reports presentation of data on clinical oncology program BAL101553 at AACR meeting 30 Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016 31 Apr 19, 2016: Peloton Therapeutics Presents Positive Preclinical Data on First HIF-2a Inhibitor in Combination with Immuno-oncology Agents at 2016 AACR Annual Meeting 32 Mar 07, 2016: Data Safety and Monitoring Board Recommends Celldex Phase 3 Study of RINTEGA (rindopepimut) in Newly Diagnosed Glioblastoma be Discontinued as it is Unlikely to Meet Primary Overall Survival Endpoint in Patients with Minimal Residual Disease 32 Mar 07, 2016: VBI Vaccines Presents New Data Supporting its Glioblastoma Immunotherapy Program at the Keystone Symposia Cancer Vaccines Conference 33 Mar 03, 2016: Cryoport Supports ImmunoCellular Therapeutics' 120-Site Phase III Clinical Trial With Cold Chain Logistics 33 Clinical Trial Profile Snapshots 35 Appendix 909 Abbreviations 909 Definitions 909 Research Methodology 910 Secondary Research 910 About GlobalData 911 Contact Us 911 Disclaimer 911 Source 912
List of Tables
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region, 2016* 6 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2016* 9 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries, 2016* 10 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries, 2016* 11 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2016* 12 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2016* 13 Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase, 2016* 20 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase 2016* 21 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2016* 25 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28


List of Figures
Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Region (%), 2016* 6 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2016* 7 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2016* 8 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2016* 9 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2016* 10 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, North America, Top Countries (%), 2016* 11 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2016* 12 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2016* 13 Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, G7 Countries (%), 2016* 14 Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Phase, 2016* 15 Glioblastoma Multiforme (GBM) Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2016* 16 Proportion of Glioblastoma Multiforme (GBM) to Oncology Clinical Trials, E7 Countries (%), 2016* 17 Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Phase, 2016* 18 Glioblastoma Multiforme (GBM) Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2016* 19 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Phase (%), 2016* 20 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials In Progress by Phase, 2016* 21 Glioblastoma Multiforme (GBM) Therapeutics, Global, Clinical Trials by Trial Status, 2016* 22 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, by End Point Status, 2016* 23 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2011-2015 24 Glioblastoma Multiforme (GBM) Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2016* 25 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Key Sponsors, 2016* 26 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Top Companies by Phase, 2016* 27 Glioblastoma Multiforme (GBM) Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2016* 28 GlobalData Methodology 910

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

U.S hairbrush market is estimated to exceed USD 1.2 billion by 2022, as per a new research report by Radiant Insights, Inc. Rising population along with ascending disposable income is expected to drive industry demand. Significant rise in disposable

Read More...

Global Aerial Work Platform (AWP) truck market is expected to be valued at USD 8,003.7 million by 2022, as per a new research report by Radiant Insights, Inc. Rapid infrastructure growth due to rising real estate investment is expected to drive the i

Read More...

Global gold nanoparticles market size is expected to reach 4.99 billion by 2020, witnessing gains at a CAGR of 24.7%. Positive outlook towards the increasing applications of nanotechnology in medical and dentistry such as drug delivery systems, nanom

Read More...

Global sorbitol market size is anticipated to be reach USD 3.99 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing consumer perception towards product benefits derived from natural ingredients is expected to drive the dem

Read More...

Global activated carbon market size is likely to be valued at USD 5.3 billion by 2020; as per a new research report by Radiant Insights, Inc. Increase in commercial & residential waste water treatment demand owing to escalation in water prices is ant

Read More...
Choose License Type
Single User - US $2500
Multi User - US $5000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify